Trial Profile

A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Sponsors Janssen Pharmaceutical KK

Most Recent Events

20 Aug 2019 Pooled analysis population pharmacokinetic results of Apalutamide from seven clinical trials were published in the Clinical Pharmacokinetics.
22 Jul 2019 Status changed from active, no longer recruiting to completed.
03 Jun 2019 Planned End Date changed from 8 May 2019 to 27 May 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com